Holds 2 active US DMFs for emtricitabine, filing since 2008. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for emtricitabine, filing since 2011. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds 2 active US DMFs for emtricitabine, filing since 2010. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.
Holds one active US DMF for emtricitabine, filing since 2009. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Holds one active US DMF for emtricitabine, filing since 2006. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds 2 active US DMFs for emtricitabine, filing since 2007. Its 2025 FDA inspection closed as VAI.
Holds 2 active US DMFs for emtricitabine, filing since 2019. Its 2024 FDA inspection closed as VAI.
Holds 3 active US DMFs for emtricitabine, filing since 2006. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for emtricitabine, filing since 2017.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Open the full list with a free accountThis page filters the worldwide Emtricitabine manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free